As a consequence, a phase Ib study has been conducted to test the MEK inhibitors pimasertib combined with voxtalisib in patients with advanced solid tumors, including TNBC and BRAFV600-mutant melanoma, who progressed on BRAF inhibitors [130]. Here, MAP2K7 is linked to melanoma.